Standard BioTools Files 8-K on Financials

TL;DR

Standard BioTools dropped an 8-K on July 31st detailing financials. Check it out.

AI Summary

Standard BioTools Inc. filed an 8-K on July 31, 2024, to report on its results of operations and financial condition. The filing also includes information related to Regulation FD disclosure and financial statements and exhibits. The company, formerly known as Fluidigm Corp, is incorporated in Delaware and headquartered in South San Francisco, California.

Why It Matters

This 8-K filing provides investors with crucial updates on Standard BioTools' financial performance and operational status, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial disclosure filing and does not inherently present new risks.

Key Players & Entities

• Standard BioTools Inc. (company) — Registrant
• Fluidigm Corp (company) — Former company name
• July 31, 2024 (date) — Date of earliest event reported
• 2 Tower Place, Suite 2000 South San Francisco, California 94080 (location) — Principal executive offices address

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob

Filing Documents

• lab-20240731.htm (8-K) — 47KB
• lab-ex99_1.htm (EX-99.1) — 975KB
• 0000950170-24-088578.txt ( ) — 1202KB
• lab-20240731.xsd (EX-101.SCH) — 51KB
• lab-20240731_htm.xml (XML) — 5KB

02 - Results of Operations and Financial Condition

Item 2.02 - Results of Operations and Financial Condition On July 31, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2024. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading "Updated FY 2024 Revenue Outlook" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information set forth under the heading "Updated FY 2024 Revenue Outlook" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Standard BioTools Inc., dated July 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 31, 2024 STANDARD BIOTOOLS INC. By: /s/ Jeffrey Black Name: Jeffrey Black Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR